60 degrees pharmaceuticals announces second quarter 2025 results

A now resolved supply disruption led to q2 net product revenue decline but higher profitability due to increased usage of a cash-pay distribution model $1.97 million cash on hand, runway through march 31, 2026 washington, aug. 13, 2025 (globe newswire) -- 60 degrees pharmaceuticals, inc. (nasdaq: sxtp; sxtpw) (the “company”), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today its financial results for the second quarter of 2025, ended june 30, 2025. while net product revenues declined compared to q2 2024 due to a now resolved supply chain disruption, the company reported an increase in profitability, largely attributed to cash-pay patients using kodatef® (tafenoquine) 16-count boxes which were imported with u.s. food and drug administration (fda) consent to help mitigate a temporary disruption of supply of arakoda® 16-count boxes.
SXTP Ratings Summary
SXTP Quant Ranking